Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development.
Papillomaviruses are aetiological agents of epithelial proliferative diseases in animals and in man. It was previously demonstrated that animals inoculated with live vaccinia recombinants expressing early proteins of polyoma virus resist challenge with polyoma-tumour cells, and this approach has been extended to the development of a vaccine against papillomavirus-transformed cells. Bovine papillomavirus type 1 (BPV1), a virus responsible for dermal lesions in cattle, is a prototype virus of the papillomavirus group. Independent vaccinia recombinant viruses expressing the early E1, E2, E5, E6 or E7 open reading frames of BPV1 were tested for their ability to direct the expression of the corresponding protein in cultured cells. Recombinants were then assessed for their ability to elicit anti-tumour immunity in Fischer rats seeded with BPV1-transformed syngeneic FR3T3 cells. Retardation of tumour growth was observed in animals vaccinated with recombinants expressing E5, E6 or E7.
Meneguzzi
G
G
U273-INSERM, Centre de Biochimie du CNRS, Parc Valrose, Nice, France.
Kieny
M P
MP
Lecocq
J P
JP
Chambon
P
P
Cuzin
F
F
Lathe
R
R
D000818:Animals; D052688:Bovine papillomavirus 1 / Q000235:genetics* / Q000276:immunology; D027383:Papillomaviridae / Q000235:genetics*; D051381:Rats; D014412:Tumor Virus Infections / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000302:isolation & purification / Q000494:pharmacology; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000302:isolation & purification / Q000494:pharmacology
D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines